EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current advances and future directions in the management of HBV-related hepatocellular carcinoma

Andrew F Ibrahim, Julie Sang, Pojsakorn Danpanichkul, Kwanjit Duangsonk, Ju Dong Yang iD, Thomas A Kerr, Amit G Singal

Gastroenterology Report · 20.01.2026 · 14

DOI: 10.1093/gastro/goag060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Gastroenterology Report, online erschienen am 13.06.2026. Verfasst von Andrew F Ibrahim und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a major driver of global cancer mortality, with HCC incidence projected to rise in the coming decades and chronic hepatitis B virus (HBV) continuing to account for a substantial proportion of cases worldwide. HBV-related HCC is distinguished by dual carcinogenic pathways: direct oncogenic effects mediated by viral persistence and genomic integration, and indirect carcinogenesis arising from chronic inflammation, fibrosis, and cirrhosis. Despite the success of nucleos(t)ide analogue (NA) therapy in suppressing HBV replication and reducing HCC incidence, residual risk persists, mandating risk-stratified surveillance even during long-term viral suppression. In parallel, advances in systemic therapy, particularly immune checkpoint inhibitor (ICI)-based combinations, have established immunotherapy-based regimens as preferred first-line options for unresectable disease. Emerging data have suggested a possible role for ICIs for select patients in earlier lines of disease, including the perioperative setting or in combination with transarterial chemoembolization for patients with intermediate-stage disease. This review synthesizes clinically relevant advances across the HBV-HCC continuum: molecular pathogenesis and risk stratification tools, antiviral strategies spanning curative and palliative settings, contemporary locoregional modalities, systemic regimens including ICI-based combinations, tyrosine kinase inhibitors, and biomarker-directed agents, and special clinical scenarios, such as portal vein tumor thrombus, high viral load, pregnancy, and viral coinfections. We emphasize HBV-specific safety considerations, including rigorous mitigation of reactivation risk with NA prophylaxis and standardized HBV DNA monitoring, and highlight future directions, such as validated composite biomarkers (e.g. circulating tumor DNA-based minimal residual disease assays), optimization of immuno-oncology locoregional therapy sequencing, and the potential influence of next-generation functional-cure HBV therapeutics on long-term HCC incidence and recurrence.

Schlagwörter

Stichwörter der Autor:innen

antiviral therapyhepatitis Bhepatocellular carcinomaimmune checkpoint inhibitors

Autor:innen und Institutionen

  • School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.
  • Department of Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.
  • Department of Microbiology, Faculty of Medicine, Chiang Mai University, 110 Inthawarorot Road, Sri Phum, Mueang Chiang Mai, Chiang Mai 50200, Thailand.
  • Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
  • Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9030, USA.

ORCID-Profile: Ju Dong Yang

Zitieren

APA

Ibrahim, A. F., Sang, J., Danpanichkul, P., Duangsonk, K., Yang, J. D., Kerr, T. A., & Singal, A. G. (2026). Current advances and future directions in the management of HBV-related hepatocellular carcinoma. Gastroenterology Report, 14. https://doi.org/10.1093/gastro/goag060

Vancouver

Ibrahim AF, Sang J, Danpanichkul P, Duangsonk K, Yang JD, Kerr TA, et al. Current advances and future directions in the management of HBV-related hepatocellular carcinoma. Gastroenterology Report. 2026;14. doi:10.1093/gastro/goag060

BibTeX
@article{Ibrahim2026,
  author = {Ibrahim, Andrew F and Sang, Julie and Danpanichkul, Pojsakorn and Duangsonk, Kwanjit and Yang, Ju Dong and Kerr, Thomas A and Singal, Amit G},
  title = {Current advances and future directions in the management of HBV-related hepatocellular carcinoma},
  journal = {Gastroenterology Report},
  year = {2026},
  volume = {14},
  doi = {10.1093/gastro/goag060}
}
Kostenlos starten →